Neurocritical Care News

March is Traumatic Brain Injury Awareness Month, a condition that has led to permanent disability in more than 5 million individuals in the United States.

WEST PALM BEACH, Fla. — More than a century of scientific research has shed light on the neuroimmune interaction in multiple sclerosis, which will be key for the development of disease-specific therapies, according to Jack P. Antel, MD.

WEST PALM BEACH, Fla. — Two experts debated the issue of whether subtypes of multiple sclerosis exist, one from Europe and the other from the United States, during the final day of ACTRIMS.

The Prospera SCS system for pain management relieved pain, improved sleep and reduced opioid use at 24 months, according to interim results of the BENEFIT-03 study.

WEST PALM BEACH, Fla. — Revisions made in 2024 to the McDonald criteria allowed for the diagnosis of multiple sclerosis in a small cohort of individuals with atypical presentation, according to a speaker at ACTRIMS.

The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and older with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive.

WEST PALM BEACH, Fla. — Ocrelizumab significantly reduced the number and volume of cortical lesions associated with multiple sclerosis at 120 weeks, findings confirmed by data from a series of new imaging techniques and presented at ACTRIMS.

WEST PALM BEACH, Fla. — Large language model algorithms may be reliable for synthesizing large patient databases to more rapidly and accurately diagnose multiple sclerosis, according to a poster presented at ACTRIMS.

WEST PALM BEACH, Fla. — Treatment with fampridine may positively impact patients with multiple sclerosis who are recovering from optic neuritis, but more extensive clinical trials are required to fully assess its effectiveness, according to a poster at ACTRIMS.